Clinical utility of the clinical dementia rating scale for Parkinson’s disease dementia by Wyman-Chick, Kathryn A.
Pacific University
CommonKnowledge
School of Professional Psychology Theses, Dissertations and Capstone Projects
7-26-2013
Clinical utility of the clinical dementia rating scale
for Parkinson’s disease dementia
Kathryn A. Wyman-Chick
Pacific University
This Dissertation is brought to you for free and open access by the Theses, Dissertations and Capstone Projects at CommonKnowledge. It has been
accepted for inclusion in School of Professional Psychology by an authorized administrator of CommonKnowledge. For more information, please
contact CommonKnowledge@pacificu.edu.
Recommended Citation
Wyman-Chick, Kathryn A. (2013). Clinical utility of the clinical dementia rating scale for Parkinson’s disease dementia (Doctoral
dissertation, Pacific University). Retrieved from:
http://commons.pacificu.edu/spp/1070
Clinical utility of the clinical dementia rating scale for Parkinson’s disease
dementia
Abstract
The purpose of this study is to explore validity of the Clinical Dementia Rating Scale (CDR) in measuring
dementia among individuals with Parkinson’s disease. The CDR was created for use in patients with
Alzheimer’s disease and, to date, there are no published studies specifically examining if the CDR is
appropriate for patients with PD. The data were obtained from the National Alzheimer’s Coordinating Center
database (The NACC database is funded by National Institute on Aging grant number U01 AG016976).
There were 490 subjects (mean/SD: Age = 72.11/9.20; education = 16.09/6.07; 73.3% male) diagnosed with
dementia (n= 151), mild cognitive impairment (n= 186), or normal cognition (n = 153) by a physician.
Inclusion criteria were a diagnosis of Parkinson’s disease. Exclusion criteria were possible or probable
Alzheimer’s disease or other confounding conditions. Sensitivity, specificity, positive predictive value and
negative predictive value were calculated for the previously published CDR Global Score as well as the Sum of
Boxes cutoff scores for each of the 3 diagnostic categories. Finally, new cutoff scores were calculated using
sensitivity and specificity values derived from the Receiver Operating Characteristic curves. The results
indicate the CDR is a useful tool in identifying dementia in patients with Parkinson’s disease when the cutoff
scores are adjusted.
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Abstract 
The purpose of this study is to explore validity of the Clinical Dementia Rating Scale (CDR) in 
measuring dementia among individuals with Parkinson’s disease. The CDR was created for use 
in patients with Alzheimer’s disease and, to date, there are no published studies specifically 
examining if the CDR is appropriate for patients with PD. The data were obtained from the 
National Alzheimer’s Coordinating Center database (The NACC database is funded by National 
Institute on Aging grant number U01 AG016976). There were 490 subjects (mean/SD: Age = 
72.11/9.20; education = 16.09/6.07; 73.3% male) diagnosed with dementia (n= 151), mild 
cognitive impairment (n= 186), or normal cognition (n = 153) by a physician. Inclusion criteria 
were a diagnosis of Parkinson’s disease. Exclusion criteria were possible or probable 
Alzheimer’s disease or other confounding conditions. Sensitivity, specificity, positive predictive 
value and negative predictive value were calculated for the previously published CDR Global 
Score as well as the Sum of Boxes cutoff scores for each of the 3 diagnostic categories. Finally, 
new cutoff scores were calculated using sensitivity and specificity values derived from the 
Receiver Operating Characteristic curves. The results indicate the CDR is a useful tool in 
identifying dementia in patients with Parkinson’s disease when the cutoff scores are adjusted. 
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Clinical Utility of the Clinical Dementia Rating Scale for Parkinson’s Disease Dementia
 The purpose of this study was to calculate the sensitivity and specificity of the Clinical 
Dementia Rating Scale (CDR) in measuring dementia and mild cognitive impairment among 
individuals diagnosed with Parkinson’s disease (PD). The CDR uses a semi-structured interview 
to rate six domains associated with Alzheimer’s Disease (AD): memory, orientation, judgment 
and problem solving, community affairs, home and hobbies, and personal care. To date, there are 
no published studies specifically examining if the published CDR cutoff scores are appropriate 
for patients with PD. This paper includes an overview of neuropsychological profile of PD and 
Parkinson’s disease dementia (PDD), as well as a review of the efficacy of similar dementia 
screening tools used in PDD. 
 According to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text 
Revision (DSM-IV-TR), dementia is characterized by significant difficulty with social or 
occupational functioning caused by memory impairment and one or more of the following 
cognitive symptoms: aphasia, apraxia, agnosia, or executive dysfunction (American Psychiatric 
Association [APA], 2000). PDD is a subcortical dementia associated with the degenerative 
disorder PD and falls under the category of dementias due to other general medical conditions in 
the DSM-IV-TR (APA, 2000). In 2007, the Movement Disorder Study Task Force (MDSTF) was 
created to develop specific diagnostic criteria for PDD. According to the MDSTF, the core 
feature required for diagnosis of PDD is that the individual has received a diagnosis of PD at 
least one year prior to the development of dementia symptoms.  
 The statistics on incidence and prevalence of PDD in the community vary and are 
dependent on the age of participants, recruitment methods, and measurement tools used to assess 
dementia (Aarsland, 2010; Reid, Hely, Morris, Loy, & Halliday, 2011; Riedel et al., 2008; 
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Zakzanis, Leach, & Kaplan, 1999). Pirozzolo et al. (1982) argued that it is difficult to determine 
the precise prevalence rate, as many individuals with PD exhibit some degree of cognitive 
impairment. Riedel and colleagues (2008) examined 873 patients with PD and found the 
prevalence of dementia in their sample was 17.5 percent as measured by the Mini-Mental Status 
Exam (MMSE), 41.8 percent as measured by the Clock Drawing Test (CDT), and 43.6 percent 
as measured by the Parkinson Neuropsychometric Dementia Assessment (PANDA), while 28.6 
percent met criteria for dementia based upon DSM-IV-TR criteria.  
In a longitudinal study conducted by Marder, Tang, Cote, Yaakov, and Mayeux (1995), 
approximately 20 percent of PD patients in the sample developed dementia over the course of 
two years. Additionally, participants with PD were 1.7 times more likely to develop dementia 
than control participants after controlling for age, gender, and education (Marder et al., 1995). 
An Australian study conducted over the course of 20 years indicated that 83 percent of surviving 
participants diagnosed with PD developed dementia by 70 years of age (Reid et al., 2011).  
 Risk factors for PDD include low education, severity of extrapyramidal motor symptoms, 
and advanced age (Aarsland et al., 2005; Glatt et al., 1996; Reid et al., 2011). However, studies 
have provided mixed evidence to support the hypothesis that age of onset of PD is a significant 
risk factor for PDD (Aarsland et al., 2005; Glatt et al., 1996; Marder et al., 1995; Reid, 1992; 
Reid et al., 2011).  
Neuropsychological Profile in Parkinson’s Disease and Parkinson’s Disease Dementia 
Non-demented patients with PD often experience neuropsychological deficits related to 
the disease process, including executive dysfunction and visual-spatial problems. Additional 
features of PDD in addition to neuropsychological deficits of PD include psychological and 
behavioral characteristics. Psychological and behavioral features may include apathy, depression, 
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visual hallucinations, delusions, and excessive daytime sleepiness (Aarsland, Cummings, & 
Larsen, 2001; Emre et al., 2007; Starkstein et al., 1996). Diagnosis of PDD can be complicated 
due to these and other issues related to medication, depression, fatigue related to sleep 
disturbances and the “attribution of functional impairment due to cognitive dysfunction rather 
than motor disability” (Marti, Tolosa, & de la Certa, 2007; p. 43). Neuropsychological 
characteristics of PDD may include impairment in executive functioning, processing speed, 
visual-spatial and construction ability, working memory, and attention (Bronnick, 2005; Emre, 
2005; Emre et al., 2007; Janvin et al., 2006). The neuropsychological symptoms associated with 
PD and PDD are discussed in further detail below.  
 Executive functions and attention.  Executive functions are involved in a wide variety 
of tasks including engaging in goal-directed behavior and inhibiting behavior as well as 
planning, sequencing, shifting, and monitoring tasks (Lezak, Howieson, & Loring, 2004; Loring, 
1999). Executive dysfunction is considered one of the “cognitive hallmarks” of PD (Bronnick, 
2005; p33), and even non-demented patients with PD perform poorly on tests of executive 
functioning such as the Wisconsin Card Sorting Test and Trail Making Test B (Dubois et al., 
2007). Furthermore, patients with PD and PDD perform poorly on Verbal Fluency tasks (Dubois 
et al., 2007; Jacobs et al., 1995; Mahieux et al., 1998).  
Attention is defined as “processes that enable an individual to engage in certain cognitive 
operations while ignoring others” and the ability to maintain this focus (Loring, 1999; p. 24). 
Fluctuations in attention are common among patients with PD and PDD (Bronnick, 2005; Emre, 
2005). As a result, attentional impairment may complicate the patient’s ability to perform 
activities of daily living (ADL; Bronnick, 2005). Additionally, deficits in executive functioning 
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and attention may contribute to problems with gait, leading to an increased number of falls 
(Hausdorff et al., 2005).  
 Visual-spatial ability. A core feature of PD involves a decline in visual-spatial ability 
over the course of the patient’s lifespan (Brown & Marsden, 1986; Johnson & Galvin, 2011).  It 
has been proposed that the decline in visual-spatial abilities evident in PD patients both with and 
without dementia may be due to eye movement abnormalities associated with changes in motor 
ability (Bodis-Wollner, 2003). Additionally, visual tasks requiring a motor component may be 
difficult for patients with PD (Brown & Marsden, 1986), however performance on Block Design 
is independently correlated with severity of dementia in patients with PD (Levin et al., 1991). In 
all, visual-spatial impairment is more severe in PDD than AD, however it is more severe in Lewy 
Body Dementia (LBD) than PDD (Bronnick, 2005).  
 Verbal ability. Verbal ability is described as the “acquisition and retention of stimuli that 
are verbal or linguistic in nature” (Loring, 1999; p. 164). Pirozzolo, Hansch, Mortimer, Webster, 
and Kuskowski (1982) argued that individuals with PDD tend to have normal performance on 
vocabulary and information verbal ability tests, as well as tests designed to detect agnosia or 
apraxia. Typically patients with PD have average performance on language tasks. However, as 
PDD progresses it may involve cortical language functions, which are reflected in tasks such as 
the Boston Naming Test (Dubois et al., 2007).  Additionally, PDD patients may have 
communication deficits related to motor impairment (Bronnick, 2005), such as dysarthria 
(Tjaden, 2008).  
 Working memory. Working memory is a “limited capacity memory system that 
provides temporary storage to manipulate information for complex cognitive tasks such as 
learning and reasoning” (Loring, 1999; p. 106). Patients with PDD perform poorly on tests of 
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working memory such as Digit Span backward (Dubois et al., 2007; Lezak et al., 2012). On 
average, non-demented patients with PD do not display deficits in working memory (Zakzanis, 
Leach, & Kaplan, 1999). 
 Motor ability. Comparing performance of patients with PD to normal control groups on 
motor ability tasks may be confounded, as PD is a characterized by movement impairment. Thus, 
the difference in scores may reflect the severity of motor symptoms, rather than cognitive factors 
such as psychomotor speed and coordination (Pirozzolo et al., 1982).  
 Memory. Memory problems are less prominent in patients with PDD than in other forms 
of dementia (Bronnick, 2005). Zakzanis et al. (1999) argued that memory problems in PDD 
patients are likely secondary to degeneration of the frontal lobes and executive dysfunction. Free 
recall is often impaired in patients with PD (Ellfolk, et al., 2012). Although delayed recall of 
verbal and visual material is often impaired in patients with PDD, recognition performance is 
generally in the normal range (Breen, 1993; Lezak et al., 2012; Tröster & Fields, 1995). Because 
of this, it is sometimes believed that memory performance may improve with the use of cues 
(Lezak et al., 2012; Tröster & Fields, 1995); however there is mixed evidence to support this 
(Higginson, et al., 2005). In addition, due to visual-spatial deficits, it is common for patients with 
PD to demonstrate impaired visual memory (Song, et al., 2008).  
Psychological Profile in Parkinson’s Disease 
Individuals with PD frequently experience changes in psychological functioning as a 
result of the disease process, which often continue to affect the individual as they develop 
dementia. Depression, apathy, and sleep disturbance are common psychological features 
associated with PD (Dubious et al., 2007; Emre, 2005; Emre et al., 2007; Marsh & Friedman, 
2005). Depression is often co-morbid with PDD, however it is not certain if this is part of the 
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degenerative process of the disease, adjustment to disability, or a combination of these factors 
(Stern, 2000). A study conducted by Starkstein et al. (1990) indicated that PD patients with 
depression have more cognitive impairment and decline more rapidly than do PD patients 
without depression.  
In addition, Poewe (2003) stated, “All major antiparkinsonian drugs can induce psychosis 
in at-risk patients” (p. 580). Risk factors include advancing age, length of time since PD 
diagnosis, presence of depression, and severity of disease symptoms. PD patients taking 
dopaminergic drugs frequently experience visual hallucinations and behavioral changes 
including difficulty with impulse control and obsessive thoughts (Marsh & Friedman, 2005; 
Poewe, 2003).  
Mild Cognitive Impairment in Parkinson’s Disease 
 The International Working Group on Cognitive Impairment MCI as a condition that is 
neither normal nor demented but with evidence of functional decline; however, ADLs are 
relatively intact (Winblad et al., 2004). In 2012, the MDSTF published diagnostic criteria for 
MCI in PD (Litvan et al., 2012). PD-MCI may include some memory impairment unusual for 
age and education, but the memory impairment does not reach the level of dementia (Fernandez 
et al., 2005; Litvan et al., 2012). MCI is common in non-demented patients with PD (Caccappolo 
& Marder, 2005; Goldman & Litvan, 2011; Litvan et al., 2012). More specifically, executive 
dysfunction (Song et al., 2008) and visual-spatial deficits (Goldman & Litvan, 2011) frequently 
are found in patients with PD. However, some authors have stated there is increasing evidence to 
support the hypothesis that PD-MCI is a prodromal phase of PDD, despite the fact that MCI does 
not always evolve into full blown dementia (Goldman & Litvan, 2011; Janvin et al., 2006). 
Others have contended that there is not enough research to support this claim (Tröster, 2008).  
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The MDSTF argued that the primary difference between PD-MCI and PDD is significant 
functional impairment (Litvan et al., 2012). It can be difficult to identify MCI in PD patients 
without a clinical interview and specific screening tools, because by definition the symptoms do 
not interfere with ADLs (Fernandez et al., 2005). Additonally, prevalence rates of MCI in PD are 
not well known, as MCI is a relatively new concept and comprehensive longitudinal studies have 
not been conducted. The MDSTF has estimated that 19-38% of individuals with PD who are not 
demented meet criteria for PD-MCI (Litvan et al., 2012). A recent study conducted by Sollinger, 
Goldstein, Lah, Levey, and Factor (2010) examined 72 non-demented PD patients. The 
participants received a neurological exam and neuropsychological assessment. The results 
indicated that 52.8 percent met criteria for PD-MCI (Sollinger et al., 2010). This study highlights 
the importance of conducting research on identifying MCI in PD.  
Comparison with Lewy Body Dementia 
Similar to PD, LBD is a subcortical dementia. According to the MDSTF, if the cognitive 
symptoms appear earlier than one year after PD diagnosis, the individual meets criteria for LBD 
(Emre et al., 2007). While LBD and PDD are similar in their clinical profile, there is evidence to 
support the hypothesis that LBD and PDD are distinctly different disorders (Braak et al., 2005; 
Libow et al, 2009). Braak et al. (2005) argued that, at the cellular level, LBD “exhibits a clinical 
phenotype apparently different from PD,” however there are similarities in the brain areas 
affected by LBD and PD.  
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Comparison with Alzheimer’s Disease 
The neuropsychological profiles of individuals with PDD are distinctly different from 
individuals with AD (Aarsland, 2005; Jacobs et al., 1995; Tröster, 2008). Patients with AD 
experience more difficulty with memory and language (Mahieux et al., 1998), whereas 
individuals with PDD have greater impairment in executive functioning and attention (Anderson, 
2004; Bronnick, 2005). However, it is possible for individuals with PD and PDD to have features 
of AD (Anderson, 2004). Unlike many patients with AD, patients with PDD typically have 
insight into the nature of their cognitive problems (Emre, 2005). In addition, it is possible for the 
two conditions to co-exist (Rajput, Rozdilsky, & Rajput, 1993). 
 MCI exists as a prodromal stage for both PDD and AD. A study by Matteau and 
colleagues (2011) measured MCI in PDD and AD using the Mattis Dementia Rating Scale 
(MDRS), and they determined that the PD-MCI group was different from the AD-MCI group in 
important ways. In this study, the participants in the AD-MCI group had memory impairment, 
but the PD-MCI participants had non-memory deficits in domains such as construction, attention, 
and conceptualization. 
Neuropsychiatric symptoms are present in both PDD and AD. Aarsland, Cummings, and 
Larsen (2001) compared neuropsychiatric symptoms in 42 participants with PDD and 42 
participants with AD. The participants were matched on age, sex, and MMSE scores. 
Neuropsychiatric symptoms were measured using the Neuropsychiatric Inventory. Results 
indicated that there were significant differences between patients with PDD and AD.  In this 
study, patients with AD exhibited higher levels of apathy and aberrant motor behavior, whereas 
the PDD group had higher levels of depression and hallucinations. Although the AD group had a 
higher number of symptoms overall, the severity of symptoms in PDD was significantly greater 
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than in AD. The authors conclude that neuropsychiatric symptoms in PDD are substantially 
different than in AD, which may be due to distinct underlying neurobiological disease processes 
in the two conditions.   
In 2011, the Alzheimer’s Association and the National Institute on Aging of the National 
Institutes of Health published new criteria and guidelines for diagnosing AD. The new guidelines 
introduced two new stages of the disease: preclinical AD and MCI. Preclinical AD is defined as 
changes in biomarkers that may indicate early signs of disease before there are any symptoms in 
thoughts or behaviors. AD-MCI is defined as mild changes in memory that can be observed and 
measured but do not impair ADLs. The third stage, dementia due to AD, involves problems in 
memory, thinking, and behavior that impair ADLs (McKhann et al., 2011). Defining earlier 
stages of the disease in this way allows researchers to study diagnosis and treatment before the 
disease progresses. 
Cognitive Screening Tools for Dementia 
Many studies examining PDD use measurement tools developed for AD that do not 
sufficiently capture important domains such as executive dysfunction that may be present in non-
AD forms of dementia (Harvey et al., 2010; Sano, 2006). 
Mini-Mental Status Exam. The MMSE was created as a screening tool for dementia 
(Folstein, Folstein, & McHugh, 1975). In 2007, the MDSTF recommended that when the MMSE 
is used as a screening tool for PDD, a cutoff score of <26 be used. However they cautioned that 
the MMSE is not ideal for measuring executive dysfunction, which is a key feature of PDD 
(Dubois et al., 2007; Marti, Tolosa, & de la Cerda, 2007). Additionally, Robottom and Weiner 
(2009) pointed out that patients with PDD demonstrate executive dysfunction early in the disease 
process, and the MMSE may not be able to detect this impairment.  
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Mamikonyan et al. (2009) examined the use of the MMSE as a screening tool for MCI in 
PD. The study included 106 patients with PD who participated in neuropsychological assessment 
of memory, executive functioning, and attention.  Results of the study suggested that impairment 
in memory and executive functioning are common in adults with PD and MCI. Similarly, Nazem 
and colleagues (2009) conducted a study using the MMSE and the Montreal Cognitive 
Assessment (MoCA), and a striking finding was that cognitive impairment may be present in PD 
patients with “normal” MMSE scores. In fact, “approximately half of patients with PD with a 
normal MMSE score have cognitive impairment based on the recommended MoCA cutoff 
score,” indicating that the MoCA may be more sensitive in detecting PD-MCI (p. 304). A study 
conducted by Zadikoff and colleagues (2008) also suggested the MoCA may be a better brief 
screening tool for cognitive deficits in PD than the MMSE.  
ADAS-Cog. The Alzheimer’s Disease Assessment Scale Cognitive Behavior Section 
(ADAS-Cog) is a brief screening tool for AD that measures word recall, naming objects, 
orientation, construction, and comprehension (Cano et al., 2010). Harvey et al. (2010) conducted 
a study of the clinical utility of the ADAS-Cog for patients with PDD. Assessments were 
administered at baseline and at 4-week follow-up. Participants included 55 patients with PDD 
and 58 patients with AD from the United States, Hungary, Italy, and France. Patients with LBD 
were excluded. Additionally, participants with an MMSE score of 17 or less were separated into 
the “moderate” group and participants with a score of 18-24 were placed in the “mild” group. 
The results found that ADAS-Cog scores were highly correlated with MMSE scores for patients 
with PDD. The ADAS-Cog also showed high test-retest reliability after a 4-week delay; 
however, further research is needed to determine if it is a valid tool for tracking decline in PDD 
over an extended period of time. The authors concluded that the ADAS-Cog is a valid tool for 
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the assessment of mild and moderate dementia in patients with Parkinson’s disease, despite the 
fact it was developed for use in patients with AD (Harvey et al., 2010).  
Mattis Dementia Rating Scale-2. The Mattis Dementia Rating Scale-2 (MDRS-2) is a 
widely used assessment tool that assesses cognitive domains affected by sub-cortical and frontal 
lobe dementias including attention, initiation and perseveration, and conceptualization. The 
MDSTF recommended the MDRS-2 in the assessment of global efficiency in patients with PD, 
as the MMSE is not as sensitive in detecting subcortical changes (Dubois, et al., 2007). Matteau 
and colleagues (2012) examined the MDRS-2 in PD patients with MCI and dementia. The results 
indicated the MDSR-2 is appropriate for use in individuals with MCI and dementia; however 
there may be a ceiling effect, which makes it difficult to identify MCI in PD. The MDRS-2 does 
not measure functional impairment; it is strictly a cognitive evaluation and is used in conjunction 
with a thorough diagnostic interview.  
 Clinical Dementia Rating Scale. The CDR was developed as a tool to accurately 
differentiate between different stages of AD. Individuals with Parkinson’s disease were explicitly 
excluded from the original studies leading to development of the CDR (Hughes, Berg, Danziger, 
Cobin, & Martin, 1982). The updated CDR uses a semi-structured interview to rate performances 
across six domains associated with AD: memory, orientation, judgment and problem solving, 
community affairs, home and hobbies, and personal care (Morris, 1993). The domains are scored 
independently of each other, although memory is considered to be the primary category. The 
category with the highest ranking (i.e., greatest level of impairment) is used to determine the 
CDR global score (CDR-GS), which ranges between 0 and 3, where 0 = absence of symptoms, 
0.5 = questionable, 1 = mild, 2 = moderate, and 3 = severe dementia (Hughes et al., 1982; 
Morris, 1993). The CDR may be an ideal staging tool for PDD, as the score reflects the impact of 
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cognitive impairment on daily activities and excludes physical disability as a result of the disease 
process. 
The expanded sum of boxes score (CDR-SB) is an optional score, which uses scores from 
all six domains and ranges between 0-18 (Morris, 1993; O’Bryant, et al., 2010). In this score, all 
of the domains have equal weight. O’Bryant and colleagues (2010) used the CDR-SB to compare 
groups with MCI, probable AD, possible AD, LBD, vascular dementia, primary progressive 
aphasia, frontotemporal dementia, and “dementia other” which included alcohol-related 
dementia, dementia of undetermined etiology, progressive supranuclear palsy, prion disease, and 
Huntington’s disease. The analysis did not include participants with PDD. The study included 
12,462 participants from the National Alzheimer’s Coordinating Center (NACC) database 
including 5,115 control group participants, 2,551 patients with MCI, and 4,796 patients with 
dementia. For AD, the CDR-SB recommended cutoff scores were as follows: 0 = normal, 0.5 to 
4 = questionable, 4.5 to 9 = mild, 9.5 to 15.5 = moderate, and 16 to 18 = severe. The authors 
argued that the expanded CDR-SB is more sensitive for “tracking changes within and between 
stages of dementia” than the CDR-GS. They argued that the greater range of scores for the CDR-
SB is more beneficial for research and clinical applications than the CDR-GS scores (O’Bryant 
et al., 2010; p. 748). A limitation of this study was the exclusion of patients with PDD, therefore 
it is not known if published CDR-SB ranges are valid for this group. 
Clinical Utility of the CDR for Dementia Screening 
 The clinical utility, or ability of a test to accurately identify individuals with specific 
conditions, is critical for conducting research and evaluating patients. Sensitivity is defined as 
the proportion of individuals correctly classified by a test as having the condition; whereas 
specificity is the likelihood that the test will detect absence of the condition in individuals who 
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do not have the condition (Strauss, Sherman, & Spreen, 2006). Positive predictive power is the 
likelihood that someone with a positive test result will in fact have the condition, and negative 
predictive value reflects the probability that someone with a negative test result will in fact not 
have the condition (Glaros & Kline, 1988; Strauss, Sherman, & Spreen, 2006) Sensitivity, 
specificity, and predictive power are used to create representative cutoff scores using appropriate 
base rate characteristics of the population in question (Elwood, 1993; Glaros & Kline, 1988; 
Meehl & Rosen, 1955).  
Glaros and Kline (1988) pointed out that, “obviously, as cutting scores are altered, 
sensitivity and specificity values of tests will change as well” (p. 1015). Liepelt-Scarfone and 
colleagues (2011) examined PD-MCI using different cut-off scores on several 
neuropsychological tests that measured executive function, attention, praxis and visual function, 
psychomotor speed, list learning and word memory recall, and logical memory. They found that 
more conservative cut-off scores only detected individuals with more severe symptoms and 
lower ADLs and therefore did not detect the PD-MCI group. They stated, “Both the frequency 
and clinical profile of PD-MCI patients were relevantly dependent on the cut-off value used for 
the definition of cognitive impairment” (p. 5).  
Purpose of Current Study 
The purpose of this study was to examine the sensitivity and specificity of the CDR in 
detecting cognitive impairment among individuals diagnosed with PD. As noted above, patients 
with PDD exhibit more problems with executive functions, visual-spatial functions, and 
attention, whereas patients with AD experience more difficulty with language and memory 
(Bronnick, 2005). The CDR was developed to detect AD; many of the core symptoms of PDD 
and AD are different, therefore there may be differences in the optimal cutoff scores for PDD 
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and AD. Several authors have used CDR cutoff scores developed for AD to classify stages of 
dementia in patients with PDD (Galvin, 2006; Galvin, Pollack & Morris, 2006; Kovari et al., 
2003; Llebaria et al., 2008; Pagonabarraga et al., 2008); however to date, there are no published 
studies specifically examining if the published CDR cutoff scores are appropriate for patients 
with PD. 
On one hand, the CDR scoring is weighted more heavily for memory and it does not 
include a formal test of visual-spatial ability or executive functions, which may limit the 
usefulness of this screening tool for patients with PD. On the other hand, the MDSTF concluded 
that, “one cornerstone of the diagnosis of dementia is the evidence of an impact on daily living 
activities that cannot be attributed to motor or autonomic symptoms in the case of PDD” (Dubois 
et al., 2007; p. 2315).  The instructions for the CDR read, “Mark in only one box for each 
category, rating impairment as decline from the person’s usual level due to cognitive loss alone, 
not impairment due to other factors such as physical handicap or depression” (Morris, 1993; p. 
2413). Therefore, the usefulness of the CDR in the screening and staging of PDD may be 
enhanced by the measurement of ADLs independent of a non-cognitive disease process and 
executive functions in the form of judgment and decision-making. In this study, the CDR 
performances of three groups of patients with PD were compared: normal cognition, PD-MCI, 
and PDD. The main hypotheses of the study are listed below. 
• Because CDR-GS cutoff scores published for AD are heavily weighted for memory 
and do not include visuospatial tasks, it is hypothesized that the published cutoff 
scores will not accurately differentiate between normal cognition, PD-MCI, and PDD.  
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• The expanded CDR-SB score will be more useful than CDR-GS for patients with PD, 
as the CDR-SB includes scores from all 6 domains and memory is not scored as the 
primary domain.  
Method 
Participants 
This study was exempted from IRB oversight, as data were anonymous in the archival 
dataset. Participant data were obtained from the National Alzheimer’s Disease Coordinating 
Centers (NACC) uniform data set, which includes data from 29 National Institute on Aging-
Funded Alzheimer’s Disease Centers (Beekly et al., 2004; Beekly et al., 2007; Weintraub et al., 
2009). Informed consent was obtained by participants or their proxies at the individual centers 
where the patients were examined. All participants in the dataset had been examined using 
standardized protocols and diagnosed by experienced physicians using uniform, published 
guidelines (Beekley et al., 2004; Beekley et al., 2007). The NACC procedures require several 
quality checks of the data before they are entered into the database (Beekly et al., 2007). 
Participants from the NACC database have been classified into three diagnostic 
categories: normal cognition, MCI, and dementia based upon physician diagnosis. Inclusion 
criteria for the present study were a diagnosis of PD and complete CDR scores in the dataset. 
Individuals with PD together with probable or possible AD were specifically excluded from the 
study in order to increase internal validity of the study. Data from patients with other dementia 
syndromes such as frontotemporal degeneration, vascular dementia, or primary diagnosis of 
LBD were excluded from the present study. Data from individuals with a history of stroke 
contributing to cognitive problems, traumatic brain injury, prion disease, brain neoplasm, 
multiple system atrophy, brain surgery, and normal pressure hydrocephalus were also excluded.  
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A total of 490 participants met inclusion criteria and were analyzed in the current study. 
With respect to demographic information, age and education of the participants are listed in 
Table 1, gender is listed in Table 2, and ethnicity is listed in Table 3.  
A one-way analysis of variance (ANOVA) was conducted to evaluate significant 
differences in age between the three participant groups. Levene’s test was significant; therefore 
the three groups were not homogeneous. The one-way ANOVA was significant using the Welch 
test [Fasymp (2, 313.16) = 13.72, p < .001]. Follow up tests were conducted to evaluate pairwise 
differences among the group means. The Games-Howell post-hoc test results indicated that the 
dementia group had a significantly higher age than the PD-MCI and normal cognition groups. 
There was no significant difference in age between the PD-MCI group and the normal cognition 
group. See Table 1 for means and standard deviations.   
 A one-way ANOVA also was conducted to evaluate potential differences in education 
between the three participant groups. The one-way ANOVA was not significant, F(2, 487) = 
2.64, p = .072, indicating there were no significant differences in education levels among the 
three groups.  
Table 1 
Participant Age and Years of Education by Group 
Note: PD-MCI = Parkinson’s Disease Mild Cognitive Impairment; PDD = Parkinson’s Disease 
Dementia 
 Normal Cognition 
N = 153 
PD-MCI 
N = 186 
PDD 
N = 151 
 M
 
SD
 
M
 
SD
 
M
 
SD
 
Age
 
70.08
 
10.46
 
71.38 8.52 75.07 7.87 
Education
 
16.25
 
2.86
 
16.69
 
9.06
 
15.19 3.04 
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Table 2 
 
Gender of Participants by Group 
 Normal Cognition 
N = 153 
PD-MCI 
N = 186 
PDD 
N = 151  
Male 
(n = 359) 
 
27.8 %  
(n = 100) 
 
 
38.7% 
(n =139) 
 
 
 
33.4%  
(n = 120) 
 
Female 
(n = 131) 
40.5%  
(n = 53) 
 
35.9% 
(n = 47) 
 
23.7%  
(n = 31) 
 
Note: PD-MCI = Parkinson’s Disease Mild Cognitive Impairment; PDD = Parkinson’s Disease 
Dementia 
 
 
 
Table 3 
Number of Participants by Group 
 
Normal Cognition 
N = 153 
PD-MCI 
N = 186 
PDD 
N = 151 
    
Caucasian  
N = 460 
94.8% 
(n = 145) 
 
91.9% 
(n = 171) 
 
95.4% 
(n = 144) 
 
African American 
N = 18 
2.0% 
(n = 3) 
 
4.8% 
(n = 9) 
 
4.0% 
(n = 6) 
 
Asian American 
N = 5 
2.0% 
(n = 3) 
 
1.1% 
(n =  2) 
 
0% 
(n = 0) 
 
Multiethnic 
N = 7 
0.49% 
(n = 2) 
2.1% 
(n = 4) 
 
0.7% 
(n = 1) 
 
Note: PD-MCI = Parkinson’s Disease Mild Cognitive Impairment; PDD = Parkinson’s Disease 
Dementia 
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Statistical Analysis 
 CDR-GS and CDR-SB scores from the NACC database were analyzed in this study.  
While multiple visits were included in the dataset for some patients, scores were obtained from 
participants’ most recent visit only for this study in order to capture as many individuals with 
PD-MCI and PDD as possible, while maintaining independent observations among data 
analyzed. Descriptive data including means and standard deviations on the CDR-GS and CDR-
SB were computed for participants with normal cognition, PD-MCI, and PDD, as well as for the 
sample as a whole. 
Sensitivity, specificity, positive predictive value, and negative predictive value were 
calculated using the diagnosis of dementia as the characteristic and various cutoff scores on the 
CDR-GS and CDR-SB, following procedures outlined in Strauss, Sherman, and Spreen (2006). 
This procedure was replicated for individuals with normal cognition and for those with a 
diagnosis of PD-MCI.  
Receiver operating characteristic (ROC) curves were generated to depict the diagnostic 
accuracy of CDR-GS and CDR-SB scores in classifying MCI and dementia in patients with PD. 
These procedures were used to test the null hypothesis that the published CDR cutoff scores 
developed for AD are the same for PDD. Finally, new cutoff scores were calculated using 
sensitivity and specificity values derived from the ROC curves.  
Results 
Table 4 displays means and standard deviations of the CDR subscale scores, global score, 
and sum of boxes score for each group.  
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Table 4 
Clinical Dementia Rating Scale Scores by Group 
 Normal  
Cognition
 
PD-MCI
 
PDD
 
 M   SD M SD M SD 
CDR Memory 0.08 0.21 1.34  0.21 1.34 0.76 
CDR Orientation  0.02 0.11 0.12 0.24 0.99 0.81 
CDR Judgment 0.05  0.18 0.41 0.31 1.35 0.78 
CDR Community Affairs 0.06  0.19 0.33 0.38 1.37 0.81 
CDR Home and Hobbies 0.05  0.18 0.32 0.34 1.48 0.88 
CDR Personal Care 0.01   0.11 0.10 0.39 1.05 1.15 
CDR-GS 0.09  0.21 0.50 0.18 1.36 0.80 
CDR-SB 0.27 0.77 1.78 1.26 7.59 4.65 
Note: PD-MCI = Parkinson’s Disease Mild Cognitive Impairment; PDD = Parkinson’s Disease 
Dementia; CDR = Clinical Dementia Rating Scale, CDR-GS = Clinical Dementia Rating Scale 
Global Score, CDR-SB = Clinical Dementia Rating Scale Sum of Boxes Score 
 
 
CDR-GS Sensitivity and Specificity 
Tables 5-7displays the proportion of true positives, true negatives, false positives, and 
false negatives for classification of those with normal cognition, PD-MCI, or PDD based on the 
results of previously published CDR-GS cutoff scores (Morris, 1993). 
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Table 5 
Sensitivity and Specificity of Clinical Dementia Rating Scale Global Score Published Norms in 
Participants with Normal Cognition  
 
 
Participants with 
Normal Cognition  
 
Participants with 
abnormal cognition  
 
 
CDR-GS indicates 
normal cognition 
 (0-.5) 
 
 151 
 
206 
 
 
PPV = 42.3% 
CDR-GS is within 
abnormal range (>1) 
2 
 
131 
 
NPV = 98.4% 
 
Sensitivity  = 
98.7% 
 
Specificity =  
38.9% 
 
 
Note: CDR-GS = Clinical Dementia Rating Scale Global score; PPV = Positive Predictive 
Value; NPV = Negative Predictive Value 
 
 
 
Table 6 
 
Sensitivity and Specificity of Clinical Dementia Rating Scale Global Score Published Norms in 
Participants with Mild Cognitive Impairment  
 
 
Participants with 
PD-MCI  
 
Participants without  
PD-MCI 
 
 
CDR-GS indicates 
MCI (1) 
 
12 
 
69 
 
 
PPV = 14.8% 
CDR-GS outside of 
MCI range  
(0-.5, 2-3) 
174 
 
255 
 
NPV = 59.4% 
 
Sensitivity  = 
6.5% 
 
Specificity =  
78.7% 
 
 
Note: CDR-GS = Clinical Dementia Rating Scale Global score; PD-MCI = Parkinson’s Disease 
Mild Cognitive Impairment; PPV = Positive Predictive Value; NPV = Negative Predictive Value 
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Table 7 
 
Sensitivity and Specificity of Clinical Dementia Rating Scale Global Score Published Norms in 
Participants with Dementia  
 
 
Participants with 
PDD  
 
Participants without 
PDD  
 
 
CDR-GS indicates 
dementia 
 (2-3) 
 
 52 
 
0 
 
 
PPV = 100% 
CDR-GS does not 
indicate dementia  
(< 1) 
99 
 
339 
 
NPV = 77.4% 
 
Sensitivity  = 
34.4% 
 
Specificity =  
100% 
 
 
Note: CDR-GS = Clinical Dementia Rating Scale Global score; PDD = Parkinson’s Disease 
Dementia PPV = Positive Predictive Value; NPV = Negative Predictive Value 
 
CDR-GS ROC Curve  
ROC curve analyses were conducted for the CDR-GS for each group. Figures 1-3 display 
the discriminant properties of the CDR-GS score (left line) for each diagnosis against the 
reference line (diagonal line). According to the ROC curve for CDR-GS, a cutoff score of 0 
yielded the best sensitivity and specificity (.84 and .98, respectively) for the normal cognition 
group. The Area Under the Curve (AUC) was 0.07 (95% CI = 0.05-0.10). A CDR-GS score of 
.05 yielded the best sensitivity and specificity for the PD-MCI group (.88 and .82, respectively). 
The AUC was 0.51 (95% CI = 0.56-0.56). Finally, for individuals with PDD, a CDR-GS of  >1 
yielded the best sensitivity and specificity (.79 and .96, respectively). The AUC was 0.92 (95% 
CI = 0.90-0.95). 
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Figure 1. Receiver Operator Characteristics Curve Analysis: Clinical Dementia Rating Scale 
Global Score for Normal Cognition  
 
 
Figure 2. Receiver Operator Characteristics Curve Analysis: Clinical Dementia Rating Scale 
Global Score for Mild Cognitive Impairment  
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Figure 3. Receiver Operator Characteristics Curve Analysis: Clinical Dementia Rating Scale 
Global Score for Dementia 
 
CDR-SB Sensitivity and Specificity 
Tables 8-10 displays the proportion of true positives, true negatives, false positives, and 
false negatives for classification of those with normal cognition, PD-MCI, or PDD based on the 
results of published CDR-SB cutoff scores (Morris, 1993; O’Bryant, et al., 2010). 
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Table 8 
Sensitivity and Specificity of Clinical Dementia Rating Scale Sum of Boxes Score Published 
Norms in Participants with Normal Cognition  
 
 
Participants with 
Normal Cognition  
 
Participants with 
abnormal cognition  
 
 
CDR-SB indicates 
normal cognition 
 (.5-4) 
 
 152 
 
43 
 
 
PPV = 77.9% 
CDR-SB is within 
abnormal range (>4.5) 
1 
 
294 
 
NPV = 100% 
 
Sensitivity  = 
99.3% 
 
Specificity =  
87.2% 
 
 
Note: CDR-SB = Clinical Dementia Rating Scale Sum of Boxes score; PPV = Positive 
Predictive Value; NPV = Negative Predictive Value 
 
Table 9 
Sensitivity and Specificity of Clinical Dementia Rating Scale Sum of Boxes Score Published 
Norms in Participants with Mild Cognitive Impairment 
 
 
 
Participants with 
PD-MCI  
 
Participants without  
PD-MCI 
 
 
CDR-SB indicates 
MCI (4.5-9) 
 
 144 
 
61 
 
 
PPV = 70.2% 
CDR-SB outside of 
MCI range (0-4, 9.5-
18) 
42 
 
247 
 
NPV = 85.5% 
 
Sensitivity  = 
77.4% 
 
Specificity =  
80.2% 
 
 
Note: CDR-SB = Clinical Dementia Rating Scale Sum of Boxes score; PD-MCI = Parkinson’s 
Disease Mild Cognitive Impairment; PPV = Positive Predictive Value; NPV = Negative 
Predictive Value 
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Table 10 
Sensitivity and Specificity of Clinical Dementia Rating Scale Sum of Boxes Score Published 
Norms in Participants with Dementia  
 
 Participants with PDD  
 
Participants without  
PDD 
 
 
CDR-SB indicates dementia 
 (9.5-18) 
 
52 
 
0 
 
PPV = 
100% 
CDR-SB does not indicate dementia  
(< 9) 
99 
 
339 
 
NPV = 
77.4% 
 Sensitivity  = 33.8% 
 
Specificity =  
100% 
 
 
Note: CDR-SB = Clinical Dementia Rating Scale Sum of Boxes score; PDD = Parkinson’s 
Disease Dementia; PPV = Positive Predictive Value; NPV = Negative Predictive Value 
 
CDR-SB ROC Curve 
ROC curve analyses were conducted for the CDR-SB for each group. Figures 4-6 display 
the discriminant properties of the CDR-SB score (left line) for each diagnosis against the 
reference line (diagonal line). In individuals with normal cognition, a CDR-SB score between 0- 
.5 yielded the best sensitivity and specificity (.91 and .87, respectively). The AUC was 0.05 
(95% CI = 0.03-0.07). For the CDR-SB, a score between 1-4 provided the best sensitivity and 
specificity (.71 and .82, respectively) in individuals with PD-MCI. The AUC was 0.48 (95% CI 
= 0.43-0.54). Finally, for individuals with PDD, the ideal CDR-SB cutoff score is > 4.5, which 
yielded the best sensitivity and specificity (.74 and .98, respectively). The AUC was 0.97 (95% 
CI = 0.96-0.98). 
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Figure 4. Receiver Operator Characteristics Curve Analysis: Clinical Dementia Rating Scale 
Sum of Boxes Score for Normal Cognition  
 
 
Figure 5. Receiver Operator Characteristics Curve Analysis: Clinical Dementia Rating Scale 
Sum of Boxes Score for Mild Cognitive Impairment  
UTILITY OF CDR FOR PARKINSON’S DISEASE DEMENTIA                                             27                       
 
Figure 6. Receiver Operator Characteristics Curve Analysis: Clinical Dementia Rating Scale 
Sum of Boxes Score for Dementia  
 
 
Overall Sensitivity and Specificity for the CDR 
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 Table 11 displays a comparison of CDR cutoff scores published by the test developers 
and the recommended CDR cutoff scores for individuals with PD found in this study. Table 12 
provides sensitivity and specificity values for published cutoff scores in individuals with PD and 
sensitivity and specificity values for the recommended cutoff scores found in this study. The 
recommended values for CDR-GS normal cognition found in this study had a slightly lower 
sensitivity value than for published scores, however specificity has increased. For the CDR-SB, 
sensitivity values for the normal and PD-MCI groups were slightly lower than for published 
scores, however this was considered acceptable as a trade-off for increasing sensitivity and 
specificity for the dementia group.  
 
 
Table 11 
A Comparison of Clinical Dementia Rating Scale Published Cutoff Scores and Recommended 
Cutoff Scores for Parkinson’s Disease Found in this Study 
 CDR-GS
 
CDR-SB
 
 Published 
cutoff scores 
 
Recommended 
cutoff scores 
 
Published 
cutoff scores  
Recommended 
Cutoff Scores 
 
 
Normal Cognition 0-0.5* 0 0-4** 0-0.5 
PD-MCI 1 0.5 4.5-9 1-4 
PDD 2-3 > 1 9.5-18 > 4.5 
 
Note: CDR-GS = Clinical Dementia Rating Scale Global Score; CDR-SB = Clinical Dementia 
Rating Scale Sum of Boxes Score; MCI = Parkinson’s Disease Mild Cognitive Impairment; PDD 
= Parkinson’s Disease Dementia 
*0.5 = “questionable” impairment 
** 0-4 = “questionable” impairment 
 
UTILITY OF CDR FOR PARKINSON’S DISEASE DEMENTIA                                             29                       
Table 12 
Comparison of Sensitivity and Specificity Values for the Clinical Dementia Rating Scale for 
Patients with Parkinson’s Disease 
 
 CDR-GS
 
CDR-SB
 
 Published 
cutoff scores 
Sensitivity/ 
Specificity   
Recommended 
cutoff scores 
Sensitivity/ 
Specificity 
Published 
cutoff scores 
Sensitivity/ 
Specificity 
Recommended 
Cutoff Scores 
Sensitivity 
/Specificity 
 
Normal Cognition .99/.39 .84/.98 .99/.87  .91/.87 
PD-MCI .07/.79 .88/.82 .77/.80 .71/.82 
PDD .34/1.0  .79/.96 .34/1.0 .74/.98 
Note: CDR-GS = Clinical Dementia Rating Scale Global Score; CDR-SB = Clinical Dementia 
Rating Scale Sum of Boxes Score; PD-MCI = Parkinson’s Disease Mild Cognitive Impairment; 
PDD = Parkinson’s Disease Dementia 
 
Discussion 
 The results indicate that the CDR is a useful tool in identifying dementia in patients with 
PD when the cutoff scores are adjusted. The present findings on the CDR compare favorably to 
sensitivity and specificity values of the MDRS-2 for dementia (sensitivity = 1.0; sensitivity = 
1.0) and for MCI (sensitivity = 0.86; sensitivity = 0.54; Matteau, et al., 2012); however the CDR 
does not measure cognitive impairment in the same way as the MDRS-2. The MDRS-2 
objectively measures cognitive functioning, and the CDR uses a diagnostic interview to assess 
functional impairment.  It is important to note the CDR is a brief screening tool and it is not 
adequate for assessing all cognitive and functional domains. More detailed neuropsychological 
evaluation may be necessary for differential diagnosis. Further studies may examine the use of 
the MDRS-2 together with the CDR to measure cognitive changes in PD.  
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The first hypothesis in the study was upheld. The CDR-GS published cutoff scores did 
not accurately categorize individuals with MCI or dementia; however, individuals with normal 
cognition were accurately categorized. The second hypothesis was partially upheld. The 
expanded CDR-SB scores were more useful than CDR-GS scores for patients with PD; however, 
this was only true for the PD-MCI group. The CDR-SB did not have greater 
sensitivity/specificity for the group with dementia. However, if the cutoff scores are adjusted, the 
CDR-GS and CDR-SB appear to be useful screening tools for normal cognition, MCI, and 
dementia in individuals with PD.  
Strengths 
One strength of this study is the large sample size that appears to be similar in many ways 
to the general population of individuals with PD. A study conducted by Baba et al. (2005) 
examined 1,264 individuals with PD and male participants made up 67% of the sample. In this 
study, 73.3% of the sample was comprised of male participants. Baba et al. (2005) argued, 
“Gender may be an important factor related to the expression of PD features during the 
symptomatic disease course” (p. 1201).  
Another strength is the quality of NACC data. All of the participants in this study were 
diagnosed with PD by a physician and received a cognitive evaluation to diagnose their cognitive 
status (i.e., normal cognition, MCI, or dementia). These detailed examinations allowed 
researchers to exclude cases with mixed etiology from this study in order to gain a pure sample 
of individuals affected by PD.  
Limitations 
 While every attempt was made to exclude cases with mixed etiology, a limitation of this 
study is the lack of neuropathological confirmation, as patients with PD may also have Lewy 
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bodies or amyloid plaques and neurofibrillary tangles, causing additional neuropathologic 
changes (Anderson, 2004; Braak et al., 2005). Therefore, generalization of these findings to 
individuals with mixed-etiology dementias should be made with caution.  
Age is a significant risk factor for dementia in PD (Aarsland et al., 2005). In this study, 
the patients with PDD were significantly older than patients with PD-MCI and the patients with 
normal cognition. There was no significant difference in age between the PD-MCI group and the 
normal cognition group.  
Morris et al. (2006) highlighted that the participants in the NACC database agreed to 
participate in longitudinal research studies at academic medical centers and may underrepresent 
the full range of individuals in the community who meet criteria for dementia. Weintraub et al. 
(2009) additionally noted that one limitation of the NACC dataset is that the participants are 
highly educated; therefore the data may not apply to the general population. In this study, the 
mean level of education was equivalent to a bachelor’s degree, and education may protect 
patients with PD from the early effects of cognitive decline (Glatt et al., 1996).  
In the present study, 93.9% of the participants were Caucasian. A large-scale study 
conducted among US Medicare beneficiaries indicated that Caucasian participants were 50% 
more likely to have PD than African American or Asian participants (Wright Willis et al., 2012). 
However, the sample in the present study may not accurately reflect the distribution of PD 
among individuals from different ethnic backgrounds and is a major limitation of this study. 
Several barriers exist in the recruitment of older adults from culturally diverse backgrounds for 
participation in research including the sampling approach used by the research coordinators: lack 
of culturally relevant incentives for participation, history of discrimination in healthcare settings, 
mistrust of involvement in research due to historical events (e.g., Tuskegee), and lack of 
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community involvement of the institutions conducting research (Feldman et al., 2008). The data 
utilized in this study were archival and therefore it was impossible to address such recruiting 
issues in this study. However, it would be important for future researchers utilizing community 
samples of patients with PD to develop culturally relevant methods of recruiting participants 
from culturally diverse backgrounds in order to reflect the general population of patients with 
PD.  
Summary 
 In summary, the present study supports the use of the CDR in patients with PD when the 
cutoff scores are adjusted. This provides researchers and clinicians a means of measuring the 
various stages of cognitive impairment in individuals with PD. Future research should focus on 
replicating this study in community samples.  
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